Codiak BioSciences, Inc.

Codiak BioSciences, Inc. (CDAK) priced its initial public offering on Oct 14, 2020 at $15.00 per share, within its $14.00–$16.00 range, raising $82.5M, and listed on Nasdaq Global Market. At the IPO price its market capitalization was about $278.9M. Goldman Sachs was lead-left underwriter, joined by Evercore ISI, William Blair and Wedbush. Goodwin Procter advised the company and Ropes & Gray advised the underwriters.

Codiak BioSciences, Inc. is a clinical-stage biopharmaceutical company developing exosome-based therapeutics. Its engEx Platform is used to design, engineer and manufacture engineered exosomes aimed at diseases including oncology, neuro-oncology and neurology, and no exosome-based therapeutic has yet been approved.

Status

IPO

Ticker

CDAK

Exchange

Nasdaq Global Market

Priced

Oct 14, 2020

IPO price

$15.00

Price range

$14.00–$16.00

Raised

$82.5M

Market cap at IPO price

$278.9M

First filed

Apr 29, 2019

Underwriters

Goldman Sachs, Evercore ISI, William Blair and Wedbush

Company counsel

Goodwin Procter

Underwriters' counsel

Ropes & Gray

Sector

Biotech & pharma

Country / state

MA

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.